Cerenis Therapeutics Holding SA

Cerenis Therapeutics Holding SA (Cerenis Therapeutics SA) is a France-based multinational biopharmaceutical company primarily engaged in the research, development and commercialization of High-density Lipoprotein (HDL) therapies for the treatment of cardiovascular and metabolic diseases. Cerenis Therapeutics Holding's product portfolio comprises Cerenis HDL and HDL enhancers that is designed to regress atherosclerotic plaque among patients at high risk of cardiovascular events, among others. Additionally, the Company has a portfolio of clinical and preclinical HDL programs. The Company is present in Labege in Midi-Pyrenees in France and in Ann Arbor in Michigan in the United States. In addition, it also operates through LYPRO Biosciences Inc.
  • TickerCEREN
  • ISINFR0012616852
  • ExchangeEuronext Paris
  • SectorPharmaceuticals & Biotechnology
  • CountryFrance

Analysts

GlobalData Department

Cerenis Therapeutics Holding SA (CEREN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary Cerenis Therapeutics Holding SA (Cerenis) is a biopharmaceutical company that discovers and develops HDL therapies for the treatment of cardiovascular and metabolic diseases. The company develops a portfolio of HDL therapies including HDL mimetics for the rapid regression of atherosclerotic plaque in high-risk patients such as patients with HDL deficiency, and post-ACS patients. It also develops drugs that increase HDL for patients with low number of HDL particles to treat atherosclerosis and related metabolic diseases. Cerenis works in partnership with other research and biotechnolog...

1 director bought

A director at Cerenis Therapeutics bought 56,179 shares at 1.780EUR and the significance rating of the trade was 60/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The n...

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

GlobalData Department

Cerenis Therapeutics Holding SA (CEREN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary Cerenis Therapeutics Holding SA (Cerenis) is a biopharmaceutical company that discovers and develops HDL therapies for the treatment of cardiovascular and metabolic diseases. The company develops a portfolio of HDL therapies including HDL mimetics for the rapid regression of atherosclerotic plaque in high-risk patients such as patients with HDL deficiency, and post-ACS patients. It also develops drugs that increase HDL for patients with low number of HDL particles to treat atherosclerosis and related metabolic diseases. Cerenis works in partnership with other research and biotechnolog...

Jehanne Leroy

Proxy Report 25/06/2018

Le conseil de Cerenis Therapeutics est désormais majoritairement indépendant (57%), ce dont nous félicitons la société. Par ailleurs, aucun administrateur ne cumule un nombre excessif de mandats et tous présentent des taux de présence supérieurs à 89% ; ainsi, Proxinvest soutient tous les renouvellements et nominations d'administrateurs proposés (résolutions 6 à 11). Concernant la rémunération 2017 du Directeur Général, on regrettera que la société ne communique pas les taux de réalisation de chacun des critères du bonus 2017 puisque sans cette information, l'actionnaire ne peut pas comprendr...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch